His life is written in the lines of his face. What’s the next chapter? LUCRIN SUPPORT FOR LIVING WELL†1 Exercise and health education in the Man Plan® † PBS Information: Authority Required (STREAMLINED: 3229). Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate. Please review Product Information before prescribing. To have a copy of the Product Information sent to you telephone: 1800 043 460. MINIMUM PRODUCT INFORMATION Lucrin Depot Prefilled Dual-Chamber Syringe (PDS) Injection (Sterile leuprorelin acetate for suspension) INDICATIONS Palliative treatment of metastatic or locally extensive prostatic cancer (Stage C and D). CONTRAINDICATIONS Nonapeptide and excipient hypersensitivity; pregnancy; lactation PRECAUTIONS Urinary tract obstructions; hyperglycaemia, increased risk of developing diabetes, increased risk of developing myocardial infarction, sudden cardiac death and stroke have been reported in men receiving GnRH agonists; QT prolongation; metastatic vertebral lesions, bone mineral density changes, convulsions. ADVERSE EFFECTS ‘Flare’ phenomenon; hot flushes; sweats; peripheral oedema; GI upset; testosterone effects; pain; dyspnoea; asthenia. Reported for Depot 3 Month and Depot 4 Month only: nervous system disturbances; arthralgia; myalgia; respiratory disorders; urinary disorders; skin reactions; others. See full PI. DOSAGE Intramuscular injection. Vary site of administration. 7.5mg injection monthly. 22.5mg injection 3 monthly. 30mg injection 4 monthly. DATE OF PREPARATION January 2013, based on Product Information last updated January 2013, Version 08. Reference: 1. The Man Plan Patient Support Program, developed by AbbVie Pty Ltd, Oct 2010. ®Registered trademark of AbbVie Pty Ltd. ABN 48 156 384 262. 32-34 Lord Street, Botany NSW 2019. Ph: 1800 043 460. AU-LUC-2013-55a June 2013